

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:	Reference	Country
NOVO NORDISK A/S	NOVO NORDISK A/S	
Corporate Patents		
Novo Alle	Agent	Short title
DK-2880 Bagsværd	Slk	06. SEP. 1999
DANEMARK	Action	Term
	Slk 99 08 08	Mfag 99 08 06
		netoet

Date of mailing (day/month/year) 26 August 1999 (26.08.99)		IMPORTANT NOTICE	
Applicant's or agent's file reference 5469.204-WO			
International application No. PCT/DK99/00068	International filing date (day/month/year) 17 February 1999 (17.02.99)	Priority date (day/month/year) 17 February 1998 (17.02.98)	
Applicant NOVO NORDISK A/S et al			

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
AU,CN,EP,IL,JP,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:  
AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,CA,CH,CU,CZ,DE,DK,EA,EE,ES,FI,GB,GD,GE,GH,GM,HR,HU, ID,IN,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,PL,PT,RO,RU,SD, SE,SG,SI,SK,SL,TJ,TM,TR,TT,UA,UG,UZ,VN,YU,ZW  
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 26 August 1999 (26.08.99) under No. WO 99/42566

**REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)**

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

**REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))**

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer J. Zahra
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C12N 9/20, C11D 3/386</p>	A1	<p>(11) International Publication Number: WO 99/42566 (43) International Publication Date: 26 August 1999 (26.08.99)</p>
<p>(21) International Application Number: PCT/DK99/00068 (22) International Filing Date: 17 February 1999 (17.02.99)</p> <p>(30) Priority Data: 0217/98 17 February 1998 (17.02.98) DK 60/076,365 27 February 1998 (27.02.98) US</p> <p>(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Corporate Patents, Novo Alle, DK-2880 Bagsvaerd (DK).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BORCH, Kim [DK/DK]; Novo Nordisk A/S, DK-2880 Bagsvaerd (DK). VIND, Jesper [DK/DK]; Novo Nordisk A/S, DK-2880 Bagsvaerd (DK). SVENDSEN, Allan [DK/DK]; Novo Nordisk A/S, DK-2880 Bagsvaerd (DK). PETERSEN, Dorte, Aaby [DK/DK]; Novo Nordisk A/S, DK-2880 Bagsvaerd (DK). PATKAR, Shamkant, Anant [DK/DK]; Novo Nordisk A/S, DK-2880 Bagsvaerd (DK). BOJSEN, Kirsten [DK/DK]; Novo Nordisk A/S, DK-2880 Bagsvaerd (DK).</p> <p>(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Alle, DK-2880 Bagsvaerd (DK).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: LIPASE VARIANT</p> <p>(57) Abstract</p> <p>Variants of Lipolase® (wild-type <i>Humicola lanuginosa</i> lipase) with a certain distribution of electrically charged amino acids have a particularly good first-wash performance in a detergent solution with a high ratio of anionic to non-ionic surfactant. The effect is achieved by attaching a positively charged peptide extension at the N-terminal and by imposing certain restrictions on the charge distribution in the region corresponding to amino acid positions 90-101 and at position 210. The inventors further devised a method of developing variants with such performance from Lipolase by attaching a peptide extension at the N-terminal and substituting amino acids in the region 90-101 or in the immediate surroundings in the three-dimensional structure. The lipases may further provide additional benefits, such as whiteness maintenance and dingy cleanup.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroun	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## LIPASE VARIANT

### FIELD OF THE INVENTION

The present invention relates to lipase variants suited for use in detergent compositions, particularly detergents with a high content of anionic surfactant. More particularly, the invention relates to variants of the wild-type lipase from *Humicola lanuginosa* strain DSM 4109.

### BACKGROUND OF THE INVENTION

For a number of years, lipases have been used as detergent enzymes to remove lipid or fatty stains from clothes and other textiles, particularly a lipase derived from *Humicola lanuginosa* (EP 258 068 and EP 305 216) sold under the tradename Lipolase<sup>®</sup> (product of Novo Nordisk A/S).

WO 92/05249, WO 94/25577, WO 95/22615, WO 97/04079 and WO 97/07202 disclose variants of the *H. lanuginosa* lipase having improved properties for detergent purposes. Thus, WO 97/04079 discloses variants having a peptide addition (extension) at the N-terminal. WO 97/07202 discloses lipase variants with "first wash performance" which are capable of removing substantial amounts of lard from a lard stained swatch in a one-cycle wash.

There is an ever existing need for providing novel lipases with improved properties, in particular improved washing properties in commercial detergents, including detergents with a high content of anionic surfactants. The present invention relates to such novel lipases.

### SUMMARY OF THE INVENTION

The inventors have found that variants of Lipolase (wild-type *Humicola lanuginosa* lipase) with a certain distribution of electrically charged amino acids have a particularly good first-wash performance in a detergent solution with a high ratio of anionic to non-ionic surfactant.

The inventors found that the effect is achieved by attaching a positively charged peptide extension at the N-terminal and by imposing certain restrictions on the charge distribution in the region corresponding to amino acid positions 90-101 and at position 210. The inventors further devised a method of developing variants with such performance from Lipolase by attaching a peptide extension at the N-terminal and substituting amino acids in the region 90-101 or in the immediate surroundings in

the three-dimensional structure. The lipases may further provide additional benefits, such as whiteness maintenance and dingy cleanup.

Accordingly, the invention provides a lipase which is a polypeptide having an amino acid sequence which:

5 a) has at least 90 % identity with the wild-type lipase derived from *Humicola lanuginosa* strain DSM 4109;

b) compared to said wild-type lipase, comprises a positively charged peptide extension attached to the N-terminal;

c) comprises a negative amino acid in position E210 of said wild-type lipase.

10 Further, the amino acid sequence may:

d) comprise a negatively charged amino acid in the region corresponding to positions 90-101 of said wild-type lipase; and

e) comprise a neutral or negative amino acid at a position corresponding to N94 of said wild-type lipase and/or has a negative or neutral net electric charge in the  
15 region corresponding to positions 90-101 of said wild-type lipase.

Alternatively, the amino acid sequence may:

d) comprise amino acids with negative or unchanged electric charge in at least two of positions N94, D96 and E99 of said wild-type lipase.

The invention also provides a detergent composition comprising the lipase, a  
20 DNA sequence encoding the lipase, an expression vector harboring the DNA sequence, a transformed host cell containing said DNA sequence or said expression vector, and a method of producing the lipase by culturing the transformed host cell.

Further, the invention provides a method of producing a variant lipase, which method comprises:

25 a) selecting a parent lipolytic enzyme having an amino acid sequence which has at least 90 % identity with the wild-type lipase derived from *Humicola lanuginosa* strain DSM 4109;

b) modifying the sequence of a nucleic acid encoding the parent lipase to produce a nucleic acid encoding a lipase which comprises a peptide extension at the  
30 N-terminal and an amino acid substitution at as location:

i) in the region corresponding to positions 90-101 of said wild-type lipase, or

ii) at the surface of the three-dimensional structure within 6 Å of any of the positions 90-101,

c) expressing the modified nucleic acid in a host cell to produce the variant li-  
35 pase,

d) testing the first-wash effect of the variant lipase in a detergent solution comprising anionic surfactant in an amount of more than 70 % by weight of the total surfactant,

- e) optionally repeating steps b-d, and
- f) selecting a variant having improved first-wash effect.

## BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 shows the construction of plasmid pEVi 1163.

5 Fig. 2 shows the construction of the *Aspergillus* vector pCaHj 483.

Fig. 3 shows the construction of the expression plasmid pCaHj 521.

## DETAILED DESCRIPTION OF THE INVENTION

### *Humicola lanuginosa* lipase

The reference lipase used in this invention is the wild-type lipase derived from  
10 *Humicola lanuginosa* strain DSM 4109. It is described in EP 258 068 and EP 305 216  
and has the amino acid sequence shown in positions 1-269 of SEQ ID NO: 2 of US  
5,869,438. In this specification, the reference lipase is also referred to as Lipolase.

### Peptide extension at N-terminal

Compared to Lipolase, the lipase of the invention comprises a positively  
15 charged peptide extension attached to the N-terminal. The peptide extension prefera-  
bly consists of 1-15 (particularly 4-10) amino acid residues, and preferably comprises  
1, 2 or 3 positively charged amino acids, most preferably 1; 2 or 3 R.

Optionally, the electric charge at the N-terminal may be further increased by  
substituting E1 with a neutral or positive amino acid, e.g. E1P.

20 Some preferred peptide extensions are SPIRR, RP(-E), SPIRPRP(-E),  
SPPRRP(-E) and SPIRPRP(-E).

The peptide extension may comprise C (cysteine) attached by a disulfide  
bridge to a second C in the polypeptide (either C present in Lipolase or introduced by  
a substitution), e.g. SPPCGRRP(-E), SPCRPR, SPCRPRP(-E), SPPCGRRPRRP(-E),  
25 SPPNGSCGRRP(-E), SPPCRRRP(-E) or SCIRR attached to E239C. Such variants  
may have improved stability.

Further, any peptide extension described in WO 97/04079 and WO 97/07202  
may be used.

### Amino acids at positions 90-101 and E210

30 The inventors have found that for good first-wash performance in anionic de-  
tergent, amino acid E210 must be negative. Thus, E210 may be unchanged or it may  
have the substitution E210D/C/Y, particularly E210D.

The lipase may comprise a negatively charged amino acid at any of positions 90-101 (particularly 94-101), e.g. at position D96 and/or E99.

Further, the lipase may comprise a neutral or negative amino acid at position N94, i.e. N94(neutral or negative), e.g. N94N/D/E.

5 Also, the lipase may have a negative or neutral net electric charge in the region 90-101 (particularly 94-101), i.e. the number of negative amino acids is equal to or greater than the number of positive amino acids. Thus, the region may be unchanged from Lipolase, having two negative amino acids (D96 and E99) and one positive (K98), and having a neutral amino acid at position 94 (N94), or the region  
10 may be modified by one or more substitutions.

Alternatively, two of the three amino acids N94, N96 and E99 may have a negative or unchanged electric charge. Thus, all three amino acids may be unchanged or may be changed by a conservative or negative substitution, i.e. N94(neutral or negative), D(negative) and E99(negative). Examples are N94D/E and  
15 D96E. Also, one of the three may be substituted so as to increase the electric charge, i.e. N94(positive), D96(neutral or positive) or E99 (neutral or positive). Examples are N94K/R, D96I/L/N/S/W or E99N/Q/K/R/H.

The substitution of a neutral with a negative amino acid (N94D/E), may improve the performance in an anionic detergent. The substitution of a neutral amino  
20 acid with a positive amino acid (N94K/R) may provide a variant lipase with good performance both in an anionic detergent and in an anionic/non-ionic detergent (a detergent with e.g. 40-70 % anionic out of total surfactant).

#### **Amino acids at other positions**

25 The inventors have found that a substitution of R209 with a neutral or negative amino acid (e.g. R209P/S) may improve the performance in anionic detergent, and that a substitution Q249R/K/H may improve the performance both in anionic and in anionic/non-ionic detergent.

G91 may be unchanged or substituted with another neutral amino acid, e.g.  
30 G91G/A/S/T. K 98 may be unchanged, or it may be substituted with a neutral or negative amino acid. N11, D137, E239 may optionally be substituted, e.g. N11E/G/K/Q/R/T, D137C/E/G/N/V/Y, E239D/G/V.

A combination of substitutions E99N+N101S may be used to introduce a glycosylation site.

### Combinations of substitutions

A lipase variant with good performance in anionic detergents may be obtained by combining a peptide extension as described above with one of the following sets of substitutions:

- 5           A. G91G/A/S/T + N94(neutral or negative) + D96D/E/C/Y + E99E/D/C/Y
- B. G91G/A/S/T + N94(neutral or negative) + D96D/E/C/Y + E99N + N101S
- C. G91G/A/S/T + N94R/K/H + D96D/E/C/Y + E99E/D/C/Y
- D. G91G/A/S/T + N94(neutral or negative) + D96(neutral or positive) + E99E/D/C/Y
- 10          E. G91G/A/S/T + N94(neutral or negative) + D96D/E/C/Y + E99(neutral or positive)
- F. any of A-E combined with Q249R.
- G. any of A-F combined with R209(neutral or negative)
- H. any of A-G combined with K98(neutral or negative)
- 15          I. Any of the above combinations further combined with any of the substitutions mentioned previously.

A lipase variant with good performance in both anionic and anionic/non-ionic detergents may be obtained by combining a peptide extension as described above with one of the following sets of substitutions:

- 20           G91A + E99R/K/H + Q249R/K/H
- G91A + N94R/K/H + Q249R/K/H
- G91A + D96(neutral or positive) + Q249R/K/H

### 25 Nomenclature for amino acid modifications

The nomenclature used herein for defining mutations is essentially as described in WO 92/05249. Thus, E99N indicates a substitution of E in position 99 with N. D96I/L/N/S/W indicates substitution of D in position 96 with I, L, N, S or W. G91G/A/S/T indicates that G91 may be unchanged (G) or substituted with A, S or T.

30 D96X indicates a substitution of D96 with any other amino acid. N94(neutral or negative) indicates a substitution of N94 with any negative or positive amino acid.

SPCRPR indicates attachment of the peptide extension SPCRPR at the N-terminal (i.e. E1). E1SPPCGRRP or SPPCGRRP(-E) indicates the substitution E1P and attachment of the peptide extension SPPCGRRP to the substituted N-terminal.



### Amino acid grouping

In this specification, amino acids are classified as negatively charged, positively charged or electrically neutral according to their electric charge at pH 10, which is typical of the detergent of the invention. Thus, negative amino acids are E, D, C and  
5 Y, particularly E and D. Positive amino acids are R, K and H, particularly R and K. Neutral amino acids are G, A, V, L, I, P, F, W, S, T, M, N, Q. A substitution with another amino acid in the same group (negative, positive or neutral) is termed a conservative substitution.

The neutral amino acids may be divided into hydrophobic (G, A, V, L, I, P, F,  
10 W) and hydrophilic (S, T, M, N, Q).

### Amino acid identity

The lipase variant of the of the invention has an amino acid identity of at least 90 % (preferably more than 95 % or more than 98 %) with Lipolase. For purposes of the present invention, the peptide extension at the N-terminal is disregarded in the  
15 calculation of amino acid identity.

The degree of identity may be suitably determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman,  
20 S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-45), using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.

The lipase variant of the invention preferably comprises a peptide addition and 0-10 (particularly 2-6) amino acid substitutions.

### 25 Method of producing variant lipase

As stated above, the invention provides a method of producing a variant lipase from parent lipase. The parent lipase may be Lipolase or a variant thereof, e.g. having substitutions such as:

E99N+N101S+E239C+Q249R+ SPPCGRRP(-E),  
30 E99K+E239C+Q249R+ SPPCGRRP(-E)  
E99N+E239C+Q249R SPPCGRRP(-E)

The variant lipase comprises a peptide extension and an amino acid substitution. The peptide extension at the N-terminal (optionally combined with a substitution of E1) is described above.

The amino acid to be substituted may be in the region corresponding to positions 90-101 (preferably 94-101). Alternatively, the amino acid to be substituted may be at the surface of the three-dimensional structure of the lipase within 6 Å of any of the positions 90-101, e.g. an amino acid at position 83, 85-115, 118, 147, 154,  
5 174, 176-178, 181, 202-203, 206-208, 211-213, 255 or 258.

Preferred amino acids are those in region 90-101 or immediately adjacent to these, i.e. in direct contact with an amino acid in the region. Such amino acids are D102, S105, S115, D111, G112, G106, C107, R108, N178, G212, F211, P208, P207, L206, I202. Amino acids of particular interest are R108, D111, S115, N178, F211,  
10 G212, G112, especially R108 and D111.

It is of special interest to substitute with an amino acids with a different electric charge, e.g. to substitute a neutral or positive amino acid with E, D, Y or C; a neutral or negative amino acid with R, K or H; or to substitute a positive or negative amino acid with L, I, V, A, N or Q.

15 The modification of the DNA sequence may be done by methods known in the art, e.g. site-directed mutagenesis or localized random mutagenesis.

#### DNA sequence

The DNA sequence encoding the lipase variant may suitably be prepared by introducing the relevant mutations in a cDNA or genomic DNA sequence encoding the  
20 parent lipase. The mutations may be introduced in accordance with well-known techniques such as those disclosed by Sambrook et al. The DNA construct may further comprise control sequences necessary for achieving expression of the modified DNA sequence. The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic  
25 acid sequence. The promoter sequence contains transcription and translation control sequences which mediate the expression of the first wash lipolytic enzyme. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

30 The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the lipase variant. The terminator sequence may be native to the nucleic acid sequence encoding the lipase variant or may be obtained from foreign sources.

35 The control sequence may also be a suitable leader sequence, a polyadenylation sequence, a signal peptide encoding sequence, or any other transcriptional or translational regulatory sequence. In addition, the DNA construct may comprise a

DNA sequence encoding a factor necessary for producing the lipase variant in active form, a so-called lipase modulator or chaperone, cf. WO 91/00908, WO 93/13200 and EP 331 376.

### Expression vector

5 The expression vector of the invention may comprise control sequences as described above necessary for the proper expression of the DNA sequence encoding the lipase variant of the invention. The choice of expression vector will depend, e.g., on the host cell intended for use in the production of the lipase. Suitable expression vectors are disclosed, e.g., in WO 91/00908, WO 93/13200, EP 331 376 and WO  
10 95/14783.

### Host cell

The host cell may be a unicellular microorganism or a non-unicellular microorganism. The host cell may be a eukaryote, and is preferably a fungal, i.e. a yeast cell or a filamentous fungal cell.

15 The fungal host cell is preferably a filamentous fungal cell, such as a cell of *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Myceliophthora*, *Mucor*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolyocladium*, and *Trichoderma*, particularly *Aspergillus* or *Fusarium*, e.g. *A. oryzae*, *A. niger*, *A. foetidus*, *A. japonicus*, *F. oxysporum* or *F. graminearum*.

20 Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Such methods are well known in the art. The host cell is preferably deficient in one or more proteolytic enzymes or other enzyme processing means. Protease deficient host cells are well-known in the art.

25 The host cell is preferably transformed with a vector comprising a nucleic acid sequence of the invention followed by integration of the vector into the host chromosome. The transformation serves to introduce the vector into the host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration may be an advantage as the nucleic acid sequence  
30 may be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous recombination.

### Production of lipase

The variant lipase of the invention as well as the DNA sequence of the invention, the expression vector of the invention, the transformed host cell of the invention

may be prepared by methods well known in the art, e.g. as described in WO 97/04079, and WO 97/07202 or in the examples of this specification.

The host cells may be cultivated in a nutrient medium suitable for production of the lipase variant using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentation) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing lipase variant to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, *More Gene Manipulations in Fungi*, Academic Press, CA, 1991). Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the lipase variant is secreted into the nutrient medium, the variant can be recovered directly from the medium. If the variant is not secreted, it is recovered from cell lysates.

The resulting lipase variant may be recovered by methods known in the art. For example, the variant may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The recovered variant may then be further purified by a variety of chromatographic procedures, e.g., ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like.

The lipase variant of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

#### **Detergent additive**

According to the invention, the lipase may typically be used as an additive in a detergent composition. This additive is conveniently formulated as a non-dusting granulate, a stabilized liquid, a slurry or a protected enzyme. Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethylene glycol, PEG) with mean molecular weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains

from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by  
5 adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

A suitable activity range for a detergent additive containing the lipolytic en-  
10 zyme of this invention is 0.01-100 mg pure enzyme protein per g of the additive.

### DETERGENT COMPOSITION

The detergent compositions of the invention may for example, be formulated as hand and machine laundry detergent compositions including laundry additive compositions and compositions suitable for use in the pretreatment of stained fabrics,  
15 rinse added fabric softener compositions, and compositions for use in general household hard surface cleaning operations and dishwashing operations.

The detergent composition of the invention comprises the lipase of the invention and a surfactant. Additionally, it may optionally comprise a builder, another enzyme, a suds suppresser, a softening agent, a dye-transfer inhibiting agent and other  
20 components conventionally used in detergents such as soil-suspending agents, soil-releasing agents, optical brighteners, abrasives, bactericides, tarnish inhibitors, coloring agents, and/or encapsulated or non-encapsulated perfumes.

The detergent composition according to the invention can be in liquid, paste, gels, bars or granular forms. The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. in the range of 7-11, particularly 9-  
25 11. Granular compositions according to the present invention can also be in "compact form", i.e. they may have a relatively higher density than conventional granular detergents, i.e. from 550 to 950 g/l.

The lipase of the invention, or optionally another enzyme incorporated in the  
30 detergent composition, is normally incorporated in the detergent composition at a level from 0.00001% to 2% of enzyme protein by weight of the composition, preferably at a level from 0.0001% to 1% of enzyme protein by weight of the composition, more preferably at a level from 0.001% to 0.5% of enzyme protein by weight of the composition, even more preferably at a level from 0.01% to 0.2% of enzyme protein by weight of  
35 the composition.

The detergent composition of the invention may comprise the lipase in an amount corresponding to 10-50,000 LU per gram of detergent, preferably 20-5,000

LU/g, e.g. 100-1000 LU/g. The detergent may be dissolved in water to produce a wash liquor containing lipolytic enzyme in an amount corresponding to 25-15,000 LU per liter of wash liquor, particularly 100 - 5000 LU/l, e.g. 300-2000 LU/l. The amount of lipase protein may be 0.001-10 mg per gram of detergent or 0.001-100 mg per liter of wash liquor.

More specifically, the lipase of the invention may be incorporated in the detergent compositions described in WO 97/04079, WO 97/07202, WO 97/41212, PCT/DK WO 98/08939 and WO 97/43375.

### Surfactant system

The surfactant system may comprise nonionic, anionic, cationic, ampholytic, and/or zwitterionic surfactants. As described above, the lipase variants of the invention are particularly suited for detergents comprising of a combination of anionic and nonionic surfactant with 70-100 % by weight of anionic surfactant and 0-30 % by weight of nonionic, particularly 80-100 % of anionic surfactant and 0-20 % nonionic. As further described, some preferred lipases of the invention are also suited for detergents comprising 40-70 % anionic and 30-60 % non-ionic surfactant.

The surfactant is typically present at a level from 0.1% to 60% by weight, e.g. 1% to 40%, particularly 10-40 %. preferably from about 3% to about 20% by weight. Some examples of surfactants are described below.

#### 20 Anionic surfactants

Preferred anionic surfactants include alkyl sulfate, alkyl ethoxy sulfate, linear alkyl benzene sulfonate and mixtures of these.

The alkyl sulfate surfactants are water soluble salts or acids of the formula  $ROSO_3M$  wherein R preferably is a  $C_{10}$ - $C_{24}$  hydrocarbyl, preferably an alkyl or hydroxyalkyl having a  $C_{10}$ - $C_{20}$  alkyl component, more preferably a  $C_{12}$ - $C_{18}$  alkyl or hydroxyalkyl, and M is H or a cation, e.g., an alkali metal cation (e.g. sodium, potassium, lithium), or ammonium or substituted ammonium.

Alkylbenzene sulfonates are suitable, especially linear (straight-chain) alkyl benzene sulfonates (LAS) wherein the alkyl group preferably contains from 10 to 18 carbon atoms.

Suitable anionic surfactants include alkyl alkoxyated sulfates which are water soluble salts or acids of the formula  $RO(A)_mSO_3M$  wherein R is an unsubstituted  $C_{10}$ - $C_{24}$  alkyl or hydroxyalkyl group having a  $C_{10}$ - $C_{24}$  alkyl component, preferably a  $C_{12}$ - $C_{20}$  alkyl or hydroxyalkyl, more preferably  $C_{12}$ - $C_{18}$  alkyl or hydroxyalkyl, A is an ethoxy or propoxy unit, m is greater than zero, typically between about 0.5 and about 6, more preferably between about 0.5 and about 3, and M is H or a cation which can be, for

example, a metal cation (e.g., sodium, potassium, lithium, calcium, magnesium, etc.), ammonium or substituted-ammonium cation. Alkyl ethoxylated sulfates as well as alkyl propoxylated sulfates are contemplated herein. Specific examples of substituted ammonium cations include methyl-, dimethyl, trimethyl-ammonium cations and  
5 quaternary ammonium cations such as tetramethyl-ammonium and dimethyl piperdinium cations and those derived from alkylamines such as ethylamine, diethylamine, triethylamine, mixtures thereof, and the like.

Other anionic surfactants include salts (including, for example, sodium, potassium, ammonium, and substituted ammonium salts such as mono- di- and triethanolamine salts) of soap, C<sub>8</sub>-C<sub>22</sub> primary or secondary alkanesulfonates, C<sub>8</sub>-C<sub>24</sub> olefinsulfonates, sulfonated polycarboxylic acids prepared by sulfonation of the pyrolyzed product of alkaline earth metal citrates.

#### Nonionic surfactant

The surfactant may comprise polyalkylene oxide (e.g. polyethylene oxide)  
15 condensates of alkyl phenols. The alkyl group may contain from about 6 to about 14 carbon atoms, in a straight chain or branched-chain. The ethylene oxide may be present in an amount equal to from about 2 to about 25 moles per mole of alkyl phenol.

The surfactant may also comprise condensation products of primary and secondary aliphatic alcohols with about 1 to about 25 moles of ethylene oxide. The alkyl  
20 chain of the aliphatic alcohol can either be straight or branched, and generally contains from about 8 to about 22 carbon atoms.

Further, the nonionic surfactant may comprise polyethylene oxide condensates of alkyl phenols, condensation products of primary and secondary aliphatic alcohols with from about 1 to about 25 moles of ethylene oxide, alkylpolysaccharides,  
25 and mixtures hereof. Most preferred are C<sub>8</sub>-C<sub>14</sub> alkyl phenol ethoxylates having from 3 to 15 ethoxy groups and C<sub>8</sub>-C<sub>18</sub> alcohol ethoxylates (preferably C<sub>10</sub> avg.) having from 2 to 10 ethoxy groups, and mixtures thereof.

Preferred nonionic surfactants are alcohol ethoxylate, alcohol phenol ethoxylate, polyhydroxy fatty acid amide, alkyl polyglucoside and mixtures of these.

#### 30 **Builder system**

The compositions according to the present invention may further comprise a builder system. Any conventional builder system is suitable for use herein including aluminosilicate materials, silicates, polycarboxylates and fatty acids, materials such as ethylenediamine tetraacetate (EDTA), metal ion sequestrants such as aminopolyphosphonates. Phosphate builders can also be used herein.  
35

Suitable builders can be an inorganic ion exchange material, commonly an inorganic hydrated aluminosilicate material, more particularly a hydrated synthetic zeolite such as hydrated zeolite A, X, B, HS or MAP.

Detergency builder salts are normally included in amounts of from 5% to 80%  
5 by weight of the composition. Preferred levels of builder for liquid detergents are from 5% to 30%.

#### Other enzymes

The detergent composition may, in addition to the lipase of the invention, comprise other enzyme(s) providing cleaning performance and/or fabric care benefits,  
10 e.g. proteases, lipases, cutinases, amylases, cellulases, peroxidases, oxidases (e.g. laccases).

Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically or genetically modified mutants are included. The protease may be a serine protease, preferably an alkaline microbial protease or a  
15 trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279) and variants thereof.

#### Bleaching agents:

The detergent composition (especially in the case of a granular detergent)  
20 may also comprise a bleaching agents, e.g. an oxygen bleach or a halogen bleach. The oxygen bleach may be a hydrogen peroxide releasing agent such as a perborate (e.g. PB1 or PB4) or a percarbonate, or it may e.g. be a percarboxylic acid. The particle size may be 400-800 microns. When present, oxygen bleaching compounds will typically be present at levels of from about 1% to about 25%.

25 The hydrogen peroxide releasing agent can be used in combination with bleach activators such as tetra-acetylenediamine (TAED), nonanoyloxybenzene-sulfonate (NOBS), 3,5-trimethyl-hexanoyloxybenzene-sulfonate (ISONOBS) or pentaacetylglucose (PAG).

The halogen bleach may be, e.g. a hypohalite bleaching agent, for example,  
30 trichloro isocyanuric acid and the sodium and potassium dichloroisocyanurates and N-chloro and N-bromo alkane sulphonamides. Such materials are normally added at 0.5-10% by weight of the finished product, preferably 1-5% by weight.



**Model Detergents****Anionic model detergent A**

A model granular detergent (90 % anionic out of total surfactants, pH in solution 10.2) is made by mixing the following ingredients (% by weight):

- 5 8.7% anionic surfactant: LAS (C<sub>10</sub>-C<sub>13</sub>)
- 7.4% anionic surfactant: AS (C<sub>12</sub>)
- 1.8% Nonionic surfactant: alcohol ethoxylate (C<sub>12</sub>-C<sub>15</sub>, 7EO)
- 30% Zeolite P (Wessalite P)
- 18% Sodium Carbonate
- 10 5% Sodium Citrate
- 17% Sodium sulfate
- 0.3% Carboxy-Methyl-Cellulose
- 6.5% Sodium-percarbonate monohydrate
- 2.1% NOBS

**15 Anionic model detergent B**

A second model granular detergent (79 % anionic out of total surfactants, pH in solution 10.2) is made by mixing the following ingredients (% by weight):

- 27% anionic surfactant: AS (C<sub>12</sub>)
- 7% Nonionic surfactant (C<sub>12-15</sub>, 7EO)
- 20 60% Zeolite P (Wessalite P)
- 5% Sodium Carbonate
- 0.6% Sokalan CP5
- 1.5% Carboxy-Methyl-Cellulose

**Anionic/non-ionic model detergent**

25 A model detergent solution (32 % anionic out of total surfactant, pH 10.2) is made by adding the following ingredients to 3.2 mM Ca<sup>2+</sup> / Mg<sup>2+</sup> (5:1) in pure water:

- 0.300 g/l of alkyl sulphate (AS; C14-16);
- 0.650 g/l of alcohol ethoxylate (AEO; C12-14, 6EO);
- 1.750 g/l of Zeolite P
- 30 0.145 g/l of Na<sub>2</sub>CO<sub>3</sub>
- 0.020 g/l of Sokalan CP5
- 0.050 g/l of CMC (carboxy-methyl cellulose)

## MATERIALS AND METHODS

### Methods

#### Lipase activity (LU)

A substrate for lipase is prepared by emulsifying glycerin tributyrate using gum Arabic as emulsifier. Lipase activity is assayed at pH 7 using pH stat method. One unit of lipase activity (LU) is defined as the amount needed to liberate one micromole fatty acid per minute.

#### Site-directed mutagenesis

For the construction of variants of a Lipolase enzyme the commercial kit, Chameleon double-stranded, site-directed mutagenesis kit can be used according to the manufacturer's instructions.

The gene encoding the Lipolase enzyme in question is located on pAHL. In accordance with the manufacturer's instructions, the Scal site of the Ampicillin gene of pAHL is changed to a MluI site by use of the primer 7258 (SEQ ID NO: 1), thus changing the Scal site found in the ampicillin resistance gene and used for cutting to a MluI site.

The pAHL vector comprising the Lipolase gene in question is then used as a template for DNA polymerase and oligo 7258 and 7770 (SEQ ID NO: 2), thus changing the Scal site found in the Lipolase gene and without changing the amino acid sequence site.

The desired mutation (e.g. the introduction of a cysteine residue) is introduced into the Lipolase gene in question by addition of an appropriate oligos comprising the desired mutation.

## EXAMPLES

### Example 1: Construction of lipase variant

Site directed mutagenesis as described above was used to construct a plasmid harboring a gene encoding the Lipolase variant 1S, E239C, Q249R. The following primers were used.

The primer 106659 (SEQ ID NO: 3) was used to introduce E99N,N101S.

The primer 101782 (SEQ ID NO: 4) was used to introduce SPPCGRRP (-E).

The primer 9639 (SEQ ID NO: 5) was used to introduce E239C.

The primer 8829 (SEQ ID NO: 6) was used to introduce Q249R.

The mutations were verified by sequencing the whole gene. The resulting plasmid was called pEVi 1163, and a restriction map is shown in Fig. 1.

#### Construction of the *Aspergillus* vector pCaHj483

5 *Aspergillus* vector pCaHj483 shown in Fig. 2 was built from the following fragments :

a) The vector pToC65 (WO 91/17243) cut with *EcoRI* and *XbaI*.

b) A 2.7 kb *XbaI* fragment from *A. nidulans* carrying the *amdS* gene (C. M. Corrick et al. Gene 53 (1987), 63-71). The *amdS* gene is used as a selective marker  
10 in fungal transformations. The *amdS* gene has been modified so that the *BamHI* site normally present in the gene is destroyed. This has been done by introducing a silent point mutation using the primer shown in SEQ ID NO: 7.

c) A 0.6 kb *EcoRI/BamHI* fragment carrying the *A. niger* NA2 promoter fused to a 60bp DNA fragment of the sequence encoding the 5' untranslated end of the  
15 mRNA of the *A. nidulans tpi* gene. The NA2 promoter was isolated from the plasmid pNA2 (EP- B-O 383 779) fused to the 60 bp *tpi* sequence by PCR. The primer encoding the 60 bp *tpi* sequence had the sequence shown in SEQ ID NO: 8.

d) A 675 bp *XbaI* fragment carrying the *A. niger* glucoamylase transcription terminator. The fragment was isolated from the plasmid pICAMG/Term (EP 238023,  
20 application No. EP 87103806.3).

The *BamHI* site of fragment c was connected to the *XbaI* site in front of the transcription terminator on fragment d via the pIC19R linker (*BamHI* to *XbaI*)

#### Construction of the expression plasmid pCaHj 521.

The lipase variant plasmid pEVi 1163 was digested with *BamH I* and *Sal I*,  
25 and the resulting fragment encoding the lipase variant was isolated.

pCaHj 483 was digested with *BamH I* and *Xho I*, and the large vector fragment (6757) was ligated to the lipase fragment. The ligation mixture was used to transform *E. coli* DH 5a cells, and a transformant harboring the expected plasmid was isolated. The plasmid was termed pCaHj 521.

#### 30 Transformation of pCaHj 521 into JaL 228.

*Aspergillus oryzae* JaL 228 (PCT/DK 97/00037) is *Aspergillus oryzae* IFO 4177 deleted in the alkaline protease and the neutral metalloprotease I. This strain was transformed with pCaHj 521 using selection on acetamide as described in patent EP 0 531 372 B1. Transformants were spore reisolated twice. Spores from second

reisolation of each transformant were tested for lipase production in small scale fermentation (shake flasks and microtiterdishes).

### Example 2: First-Wash Performance in Anionic Detergent

A number of variants according to the invention were tested in an anionic detergent. The experimental conditions were as follows:

- Equipment: Thermostated Terg-o-tometer
- Method: 1 cycle wash followed by line drying.
- Wash liquor: 1000 ml per beaker
- Swatches: 7 (cotton style # 400) swatches (9\*9 cm) per beaker.
- 10 Stain: Lard coloured with Sudan red (0,75mg Sudan red/g lard).
- 50ml of lard/Sudan red heated to 70°C is applied to the center of each swatch. After application of the stain the swatches are heated in an oven for 25 minutes at 75°C. Stored overnight at room temperature prior to the wash.
- 15 Water: 1.07 mM Ca<sup>2+</sup>/Mg<sup>2+</sup> (5:1) ~ 6°dH
- Detergent: 1.4 g/l commercial Tide w. Bleach.
- Lipase concentration: 0. 1000 LU/l
- 20 Wash time: 12 min.
- Temperature: 25°C
- Rinse: 15 minutes in running tap water.
- Drying: Overnight at room temperature (~ 20°C, 30-40 % RH).
- Evaluation: The reflectance was measured at 460 nm at a Mach-
- 25 beth Coloreye 7000 reflectometer. The results are given as  $\Delta R$  (delta Reflectance) = reflectance of swatches washed in detergent with lipase minus reflectance of swatches washed in detergent without lipase

Mutations	N-terminal	$\Delta R$
N94K	SPPRRP(-E)	3
N94K+Q249R	SPPRRP(-E)	4
G91A+D96N+E99K+Q249R	SPIRPRP(-E)	3
G91A+D96E+E99K+Q249R	SPIRPRP(-E)	3

G91A+D96W+Q249R	SPIRPRP(-E)	3
G91A+E99K+Q249R	SPIRPRP(-E)	4
E239C	SPPCGRRP(-E)	3
S83T+N94K+D96L+E239C+Q249R	SPCRPRP(-E)	3
E99N+N101S+E239C+Q249R	SPPCGRRP(-E)	4
E99K+Q249R	SPIRPRP(-E)	2
G91A+Q249R	SPIRPRP(-E)	4
G91A+E99K	SPIRPRP(-E)	4
E99N+N101S+E239C	SPPCGRRP(-E)	4
G91A+E99N+N101S+E239C+Q249R	SPPCGRRP(-E)	3
S83T+E99N+N101S+E239C+Q249R	SPPCGRRP(-E)	5
E99N+E239C+Q249R	SPPCGRRP(-E)	3
N101S+E239C+Q249R	SPPCGRRP(-E)	2
D96S+E239C+Q249R	SPPCGRRP(-E),	3
N94S+D96L+E239C+Q249R	SPPCGRRP(-E)	3
E99K+E239C+Q249R	SPPCGRRP(-E)	3
Q249R	SPIRPRP(-E)	3
K98D+E99K+Q249R	SPIRPRP(-E)	3
E99K+D137E+Q249R	SPIRPRP(-E)	4 <sup>7</sup>
E99K,R209P,Q249R	SPIRPRP(-E)	2
E99K,R209S,Q249R	SPIRPRP(-E)	3 <sup>7</sup>
E99K,D137E,E183D,E239C,Q249R	SPPCGRRP(-E)	2
E99K,R209P,E239C,Q249R	SPPCGRRP(-E)	6
N94D,E99N,E239C,Q249R	SPPCGRRP(-E)	5
S83T+ Q249R	SPIRR	5

S83T+ E87K+ Q249R	SPIRR	3 <sup>***</sup> )
D57G+ W89F+ I90V+ G91S+ Q249R	SPIRPRP(-E)	4
E1A+ N11H+ L12I+ D137G+ V187A+ K237R+ T244S+ Q249R	SPIRR	2
N8K+ F10L+ N11C+ Q15H+ R232G+ E239C	SPPCGRRP(-E)	3
T231K+ R232G+ N233H+ E239C	SPPCGRRP(-E)	3

\* Special wash conditions: 1250 LU/l

\*\* Special wash conditions: 30°C, 20 min wash

\*\*\* Special wash conditions: 500 LU/l

- 5 For comparison, the following lipase variant according to WO 97/07202 was tested at the same conditions:

Prior art: Lipolase modified with E1SPIRPRP+ D57G+ N94K+ D96L+ L97M + Q249R

- 10 The result showed  $\Delta R = 1.3$  at 1000 LU/l of the prior-art lipase variant. Thus, the results show clearly that the lipase variants have improved first-wash effect in a detergent with mainly anionic surfactant (more than 80 % of total surfactant).

### Example 3: Comparative test for first-wash effect

A lipase variant of the invention was compared to a prior-art lipase variant according to WO97/07202, as follows:

- 15 Invention: Lipolase modified with E1SPPCGRRP+ E99N+ N101S+ E239C+ Q249R.

Prior art: Lipolase modified with E1SPPRRP+ D57G+ N94K+ D96L+ Q249R.

The two variants were tested in a commercial US detergent (Tide) in the same manner as in Example 2, using 1250 or 12,500 LU/l. Results:

20

	1250 LU/l	12,500 LU/l
Invention	4.9	11.1
Prior art	2.1	8.3

The results show in each case that the variant of the invention has a better first-wash effect in anionic detergent than the prior-art variant.

#### Example 4: First-Wash Performance in Various Detergents

The lipase variant was Lipolase with modifications E1SPPCGRRP+ E99N+  
5 N101S+ E239C+ Q249R, prepared in Example 1. The following two detergents were tested at the same conditions as in Example 2:

##### Anionic detergent

Water: 1.07 mM Ca<sup>2+</sup>/Mg<sup>2+</sup> (5:1) ~ 6°dH  
Detergent: 1.4 g/l commercial Tide w. Bleach.  
10 Lipase concentration: 0, 800, 1600, 3200, 6400, 12800 LU/l  
Wash time: 12 min.  
Temperature: 30°C

##### Anionic/non-ionic detergent

Water: 3.2 mM Ca<sup>2+</sup>/Mg<sup>2+</sup> (5:1) ~ 18°dH  
15 Detergent: 3.6 g/l commercial Ariel Futur.  
Lipase concentration: 0, 800, 1600, 3200, 6400, 12800 LU/l  
Wash time: 20 min.  
Temperature: 30°C

Variant dosage	Anionic detergent	Anionic/non-ionic detergent
800 LU/l	4	6
1600 LU/l	7	7
3200 LU/l	7	8
6400 LU/l	10	10
12800 LU/l	11	11

20 The above results show that the lipase variant has a good first-wash performance, both in a detergent with more than 80% anionic surfactant and in a detergent with about equal amounts of anionic and non-ionic surfactant.

**Example 5: Stability in detergent solutions**

To evaluate stability of the lipase variant in detergent solutions, residual activity after incubation was determined. Two detergents with high content (>80 %) of anionic surfactant were tested: a commercial US detergent (Tide w. Bleach HDP at 1.4 g/l) and a Japanese detergent (Super Compact Top at 0.5 g/l). A detergent with nearly equal amounts of anionic and non-ionic surfactants was also tested: a commercial European detergent (Ariel Futur HDP at 5 g/l).

A solution of each detergent was heated to 85°C for 5 minutes to inactivate the enzymes. The detergent solution was cooled to room temperature and the pH was adjusted to pH 10.0. Purified lipase was added to a concentration of approx. 10 LU/ml in a 5 ml volume and the solution was split into two portions:

- a) One for immediate determination of activity (reference), and
- b) One for 30 minutes incubation at 30°C (sample).

100 µl samples were taken from solutions a) and b) (upon rapid cooling) for determination in duplicate of the activity by the LU method described above.

The residual activity after incubation was calculated as the activity in sample

Surfactant	Detergent	Residual activity
Mainly anionic	US	65 %
Mainly anionic	Japanese	>90 %
Anionic + non-ionic	European	91 %

b) relative to the activity in sample a). The results were as follows:

A similar experiment with the European detergent solution at 40°C showed 61 % residual activity after 20 minutes.

The results show that the lipase variant is fairly stable in detergent solutions, both with mainly anionic surfactant and with nearly equal amounts of anionic and non-ionic surfactants.



## CLAIMS

1. A lipase which is a polypeptide having an amino acid sequence which:
  - a) has at least 90 % identity with the wild-type lipase derived from *Humicola lanuginosa* strain DSM 4109;
  - 5 b) compared to said wild-type lipase, comprises a positively charged peptide extension attached to the N-terminal;
  - c) comprises a negative amino acid in position E210 of said wild-type lipase; and
  - d) comprises a negatively charged amino acid in the region corresponding to positions 90-101 of said wild-type lipase; and
  - 10 e) comprises a neutral or negative amino acid at a position corresponding to N94 of said wild-type lipase and/or has a negative or neutral net electric charge in the region corresponding to positions 90-101 of said wild-type lipase.
  
- 15 2. A lipase which is a polypeptide having an amino acid sequence which:
  - a) has at least 90 % identity with the wild-type lipase derived from *Humicola lanuginosa* strain DSM 4109;
  - b) compared to said wild-type lipase, comprises a positively charged peptide extension attached to the N-terminal;
  - 20 c) comprises a negative amino acid in position E210 of said wild-type lipase; and
  - d) comprises amino acids with negative or unchanged electric charge in at least two of positions N94, D96 and E99 of said wild-type lipase.
  
3. The lipase of claim 1 or 2 wherein the peptide extension consists of 1-15 amino  
25 acid residues (preferably 4-10), and preferably comprises 1, 2 or 3 positively charged amino acids, preferably 1, 2 or 3 R.
  
4. The lipase of claim 3 wherein the extension is SPIRR, RP(-E), SPIRPRP(-E), SPPRRP(-E) or SPIRPRP(-E).
  
5. The lipase of any of claims 1-3 wherein the extension comprises C which is at-  
30 tached to a second C in the polypeptide, preferably SPPCGRRP(-E), SPCRPR, SPCRPRP(-E), SPPCGRRPRRP(-E), SPPNGSCGRRP(-E), SPPCRRRP(-E) or SCIRR attached to E239C.

6. The lipase of any preceding claim which comprises a substitution G91A, N94D/E/K/R, D96E/I/L/N/S/W, E99N/Q/K/R/H, N101S, R209P/S or Q249R/K/H.
7. The lipase of any preceding claim which comprises one of the following sets of substitutions, optionally combined with Q249R/K/H and/or K98X:
- 5 a) G91G/A/S/T + N94(neutral or negative) + D96D/E/C/Y + E99E/D/C/Y,  
b) G91G/A/S/T + N94(neutral or negative) + D96D/E/C/Y + E99N + N101S,  
c) G91G/A/S/T + N94R/K/H + D96D/E/C/Y + E99E/D/C/Y,  
d) G91G/A/S/T + N94(neutral or negative) + D96(neutral or positive) + E99E/D/C/Y, or  
10 e) G91G/A/S/T + N94(neutral or negative) + D96D/E/C/Y + E99(neutral or positive).
8. The lipase of any of claims 1-6 which comprises one of the following sets of substitutions, optionally combined with Q249R and/or R209(neutral or negative):
- 15 a) E99R/K/H + Q249R/K/H,  
b) N94R/K/H + Q249R/K/H, or  
c) D96(neutral or positive) + Q249R/K/H.
9. A lipase which is a variant of a parent lipase derived from *Humicola lanuginosa* strain DSM 4109 having the modifications:
- 20 a) E99N+N101S+E239C+Q249R+ SPPCGRRP(-E),  
b) E99K+E239C+Q249R+ SPPCGRRP(-E), or  
c) E99N+E239C+Q249R+ SPPCGRRP(-E).
10. A detergent composition comprising a surfactant and the lipase of any of claims 1-9.
11. The detergent composition of the preceding claim wherein the surfactant comprises anionic surfactant in an amount of more than 70 % by weight of the total surfactant.  
25
12. The detergent composition of claim 10, wherein the surfactant comprises anionic surfactant in an amount of 40-70 % by weight and nonionic surfactant in an amount of 30-60 % by weight of the total surfactant, and the lipase is the lipase of  
30 claim 8 or 9.

13. The detergent composition of any of claims 10-12 which comprises 10-40 % by weight surfactant, preferably comprises 40-70 % builder, and preferably has a pH of 9-11 when dissolved in water at 0.5-5 g/l.
14. A DNA sequence encoding the lipase of any of claims 1-9.
- 5 15. An expression vector harboring the DNA sequence of the preceding claim.
16. A transformed host cell containing the DNA sequence of claim 14 or the expression vector of claim 15.
17. A method of producing a lipase which method comprises culturing the transformed host cell of claim 16 under conditions conducive for the production of the lipase and recovering the lipase from the resulting broth.
- 10
18. A method of producing a variant lipase, which method comprises:
- a) selecting a parent lipolytic enzyme having an amino acid sequence which has at least 90 % identity with the wild-type lipase derived from *Humicola lanuginosa* strain DSM 4109;
  - 15 b) modifying the sequence of a nucleic acid encoding the parent lipase to produce a nucleic acid encoding a variant lipase which comprises a peptide extension at the N-terminal and an amino acid substitution at a location:
    - 20 i) in the region corresponding to positions 90-101 of said wild-type lipase, or
    - ii) at the surface of the three-dimensional structure within 6 Å of any of the positions 90-101,
  - c) expressing the modified nucleic acid in a host cell to produce the variant lipase,
  - 25 d) testing the first-wash effect of the variant lipase in a detergent solution comprising anionic surfactant in an amount of more than 70 % by weight of the total surfactant,
  - e) optionally repeating steps b-d, and
  - f) selecting a variant having improved first-wash effect.




Fig. 1






Fig. 2

3/4



BamH I, Xho I



BamH I, Xho I

Fig. 3




Fig. 3 (CONTINUED)

## SEQUENCE LISTING

<110> Novo Nordisk A/S

<120> LIPASE VARIANT

<130> 5469-WO

<140>

<141>

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 7258

<220>

<221> modified\_base

<222> (1)

<223> p

<400> 1

ngaatgactt ggttgacgcg tcaccagtca c

31

<210> 2

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 7770

<220>

<221> modified\_base

<222> (1)

<223> p

<400> 2

ntctagccca gaatactgga tcaaatc

27

<210> 3



<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 106659

<220>

<221> modified\_base

<222> (1)

<223> p

<400> 3

ncttaacttt gacttgaaaa acatatctga catttgctcc

40

<210> 4

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 101782

<220>

<221> modified\_base

<222> (1)

<223> p

<400> 4

nggacggcct tggetagccc tccgtgcggc cgccggcgg tctcgcagga tctgtttaac 60

<210> 5

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 9639

<220>

<221> modified\_base

<222> (1)

<223> p

<400> 5

natatcgtga agatatgagg cattgatgcc acc

33

<210> 6

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: P 8829

<220>

<221> modified\_base

<222> (1)

<223> p

<400> 6

nggcggcaat aaccggccga acattccgga tatccc

36

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 7

agaaatcggg tatectttca g

21

<210> 8

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 8

gctcctcatg gtggatcccc agttgtgtat atagaggatt gaggaaggaa gagaagtgtg 60

gatagaggta aattgagttg gaaactccaa gcatggcatc cttgc

105

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 99/00068

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>				
IPC6: C12N 9/20, C11D 3/386 According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>				
Minimum documentation searched (classification system followed by classification symbols)				
IPC6: C12N, C11D				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
SE,DK,FI,NO classes as above				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 9707202 A1 (NOVO NORDISK A/S), 27 February 1997 (27.02.97), page 22, line 22 - page 23; page 34, line 26 - page 35, line 10  --	1-18		
X	WO 9704079 A1 (NOVO NORDISK A/S), 6 February 1997 (06.02.97), page 1, lines 24-25; page 3, lines 3-5; page 7, line 28 - page 8, line 4; page 10, lines 18,33; page 11, lines 4-5,9  --	1-18		
A	WO 9600292 A1 (UNILEVER N.V.), 4 January 1996 (04.01.96), page 1, lines 22-27, 36 - page 2, line 2; page 7, line 26 - page 8, line 32  -- -----	1-18		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">           * Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" cited document but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 50%; border: none;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understate the principle or theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" cited document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understate the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" cited document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understate the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
28 May 1999	13 -06- 1999			
Name and mailing address of the ISA Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer  Carolina Palmcrantz/Els Telephone No. +46 8 782 25 00			

Form PCT:ISA/210 (second sheet) (July 1992)

NZAS-0239276

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/DK 99/00068

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9707202 A1	27/02/97	AU 6655196 A	12/03/97
		CN 1192780 A	09/09/98
		EP 0851913 A	08/07/98
		AU 6414096 A	18/02/97
		AU 6414196 A	18/02/97
		CN 1193346 A	16/09/98
		EP 0839186 A	06/05/98
		WO 9704078 A	06/02/97
		WO 9704079 A	06/02/97
		WO 9704079 A1	06/02/97
AU 6414196 A	18/02/97		
CN 1193346 A	16/09/98		
EP 0839186 A	06/05/98		
WO 9704078 A	06/02/97		
AU 6655196 A	12/03/97		
CN 1192780 A	09/09/98		
EP 0851913 A	08/07/98		
WO 9707202 A	27/02/97		
WO 9600292 A1	04/01/96	AU 2884695 A	19/01/96

Form PCT/ISA-210 (patent family annex) (July 1992)

NZAS-0239277